Bioxcel Therapeutics Earns Buy Rating on Promising Clinical Trials and Market Potential
Ram Selvaraju, H.C. Wainwright analyst, maintains Buy rating on Bioxcel Therapeutics (BTAI) with $7.00 price target, citing SERENITY At-Home Phase 3 trial initiation for BXCL501, IGALMI's post-marketing study success, and FDA's positive review of SERENITY protocol. Canaccord Genuity also reiterates Buy rating with $7.00 target.
Highlighted Terms
Related News
Bioxcel Therapeutics Earns Buy Rating on Promising Clinical Trials and Market Potential
Ram Selvaraju, H.C. Wainwright analyst, maintains Buy rating on Bioxcel Therapeutics (BTAI) with $7.00 price target, citing SERENITY At-Home Phase 3 trial initiation for BXCL501, IGALMI's post-marketing study success, and FDA's positive review of SERENITY protocol. Canaccord Genuity also reiterates Buy rating with $7.00 target.